These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 17038832)

  • 41. Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge.
    Phan SI; Zengel JR; Wei H; Li Z; Wang D; He B
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747496
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Health care costs of hospitalization of young children for respiratory syncytial virus infections: a population-based matched cohort study.
    Thampi N; Knight BD; Thavorn K; Webster RJ; Lanctot K; Hawken S; McNally JD
    CMAJ Open; 2021; 9(4):E948-E956. PubMed ID: 34667075
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop.
    Roberts JN; Graham BS; Karron RA; Munoz FM; Falsey AR; Anderson LJ; Marshall V; Kim S; Beeler JA
    Vaccine; 2016 Sep; 34(41):4843-4849. PubMed ID: 27566900
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group.
    Rodriguez WJ; Gruber WC; Welliver RC; Groothuis JR; Simoes EA; Meissner HC; Hemming VG; Hall CB; Lepow ML; Rosas AJ; Robertsen C; Kramer AA
    Pediatrics; 1997 Mar; 99(3):454-61. PubMed ID: 9041304
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
    Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S
    J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Informing randomized clinical trials of respiratory syncytial virus vaccination during pregnancy to prevent recurrent childhood wheezing: A sample size analysis.
    Riddell CA; Bhat N; Bont LJ; Dupont WD; Feikin DR; Fell DB; Gebretsadik T; Hartert TV; Hutcheon JA; Karron RA; Nair H; Reiner RC; Shi T; Sly PD; Stein RT; Wu P; Zar HJ; Ortiz JR;
    Vaccine; 2018 Dec; 36(52):8100-8109. PubMed ID: 30473186
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The use of health economics to guide drug development decisions: Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach.
    Bos JM; Rietveld E; Moll HA; Steyerberg EW; Luytjes W; Wilschut JC; de Groot R; Postma MJ
    Vaccine; 2007 Sep; 25(39-40):6922-9. PubMed ID: 17707959
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Severe outcomes associated with respiratory viruses in newborns and infants: a prospective viral surveillance study in Jordan.
    Khuri-Bulos N; Lawrence L; Piya B; Wang L; Fonnesbeck C; Faouri S; Shehabi A; Vermund SH; Williams JV; Halasa NB
    BMJ Open; 2018 May; 8(5):e021898. PubMed ID: 29780032
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of case definitions for estimation of respiratory syncytial virus associated hospitalizations among children in a rural community of northern India.
    Saha S; Pandey BG; Choudekar A; Krishnan A; Gerber SI; Rai SK; Singh P; Chadha M; Lal RB; Broor S
    J Glob Health; 2015 Dec; 5(2):010419. PubMed ID: 26649172
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South Africa.
    Koltai M; Moyes J; Nyawanda B; Nyiro J; Munywoki PK; Tempia S; Li X; Antillon M; Bilcke J; Flasche S; Beutels P; Nokes DJ; Cohen C; Jit M
    BMC Med; 2023 Mar; 21(1):120. PubMed ID: 37004062
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults.
    Falloon J; Yu J; Esser MT; Villafana T; Yu L; Dubovsky F; Takas T; Levin MJ; Falsey AR
    J Infect Dis; 2017 Dec; 216(11):1362-1370. PubMed ID: 29029260
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Respiratory syncytial virus infection and disease in infants and young children observed from birth in Kilifi District, Kenya.
    Nokes DJ; Okiro EA; Ngama M; Ochola R; White LJ; Scott PD; English M; Cane PA; Medley GF
    Clin Infect Dis; 2008 Jan; 46(1):50-7. PubMed ID: 18171213
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vaccine Induced Herd Immunity for Control of Respiratory Syncytial Virus Disease in a Low-Income Country Setting.
    Kinyanjui TM; House TA; Kiti MC; Cane PA; Nokes DJ; Medley GF
    PLoS One; 2015; 10(9):e0138018. PubMed ID: 26390032
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines.
    Wright PF; Karron RA; Belshe RB; Shi JR; Randolph VB; Collins PL; O'Shea AF; Gruber WC; Murphy BR
    Vaccine; 2007 Oct; 25(42):7372-8. PubMed ID: 17868959
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in Phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine.
    Yang CF; Wang CK; Malkin E; Schickli JH; Shambaugh C; Zuo F; Galinski MS; Dubovsky F; ; Tang RS
    Vaccine; 2013 Jun; 31(26):2822-7. PubMed ID: 23602668
    [TBL] [Abstract][Full Text] [Related]  

  • 56. RSV vaccine use--the missing data.
    Drysdale SB; Sande CJ; Green CA; Pollard AJ
    Expert Rev Vaccines; 2016; 15(2):149-52. PubMed ID: 26636902
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Challenges in developing a pediatric RSV vaccine.
    Schickli JH; Dubovsky F; Tang RS
    Hum Vaccin; 2009 Sep; 5(9):582-91. PubMed ID: 19556888
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Respiratory Syncytial Virus hospitalization burden: a nation-wide population-based analysis, 2000-2017.
    Glatman-Freedman A; Kaufman Z; Applbaum Y; Dichtiar R; Steiman A; Gordon ES; Keinan-Boker L; Shohat T; Haklai Z
    J Infect; 2020 Aug; 81(2):297-303. PubMed ID: 32504738
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Burden of respiratory syncytial virus in hospitalized infants and young children in Amman, Jordan.
    Khuri-Bulos N; Williams JV; Shehabi AA; Faouri S; Al Jundi E; Abushariah O; Chen Q; Ali SA; Vermund S; Halasa NB
    Scand J Infect Dis; 2010 May; 42(5):368-74. PubMed ID: 20100116
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.
    Kampmann B; Madhi SA; Munjal I; Simões EAF; Pahud BA; Llapur C; Baker J; Pérez Marc G; Radley D; Shittu E; Glanternik J; Snaggs H; Baber J; Zachariah P; Barnabas SL; Fausett M; Adam T; Perreras N; Van Houten MA; Kantele A; Huang LM; Bont LJ; Otsuki T; Vargas SL; Gullam J; Tapiero B; Stein RT; Polack FP; Zar HJ; Staerke NB; Duron Padilla M; Richmond PC; Koury K; Schneider K; Kalinina EV; Cooper D; Jansen KU; Anderson AS; Swanson KA; Gruber WC; Gurtman A;
    N Engl J Med; 2023 Apr; 388(16):1451-1464. PubMed ID: 37018474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.